CCT2 / T-complex protein 1 subunit beta · IHC design guide

Design Immunohistochemistry for CCT2

Plan chromogenic CCT2 IHC in paraffin sections using the cytoplasmic tissue pattern and strong staining in late spermatids as references (HPA tissue IHC). This guide covers fixation consistency, tissue controls, and staining assessment with an IHC-validated antibody.

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for CCT2 (IHC for CCT2): expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC), antibody PB9992, validated IHC image, and IHC protocol steps — Printable **CCT2** IHC protocol sheet — expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC), antibody PB9992, controls and protocol steps. Open the full CCT2 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

CCT2 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining in most tissues (HPA tissue IHC)
	Staining pattern	Cytoplasmic; high in late spermatids (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet PB9992)
	Positive control ⓘ	Testis+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific)
	Caveat	Staining and RNA show medium consistency (HPA tissue IHC)
	Regulation	Expression regulation unreported (UniProt)
	Isoform / epitope	2 isoforms; epitope coverage is unspecified (UniProt)

Section 1

Recommended CCT2 IHC & IF Protocols

The catalog antibody’s IHC-P protocol is supplemented by three published CCT2 IHC protocols from paraffin sections (PMC13485502; PMC3691597; PMC12574043).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded rat gaster tissues; fixative not specified (datasheet PB9992)
Fixation	Image fixative and duration unreported (datasheet PB9992); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet PB9992)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB9992)
Primary antibody	Rabbit anti-CCT2, 0.5-1μg/ml (datasheet PB9992)
Primary incubation	Overnight at 4 °C (datasheet PB9992)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9992)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	CCT2-positive staining in elongated or late spermatids of testis (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues, most abundant in testis. No signal in the no-primary control.

💡Decision noteStart with heat-mediated citrate retrieval at pH 6 for the catalog antibody (datasheet: PB9992); two published protocols also specify citrate retrieval (PMC13485502; PMC12574043).

Section 2

What Is the Expected CCT2 Staining Pattern?

CCT2 is a cytoplasmic protein with no transmembrane segment (UniProt P78371: subcellular location; topology). In paraffin-section IHC, expect cytoplasmic staining across many tissues, with the strongest listed signal in elongated or late spermatids in testis (HPA: tissue IHC). HPA rates the tissue profile Enhanced, while noting medium consistency between antibody staining and RNA expression; interpret intensity alongside cell identity and controls (HPA: reliability).

What am I looking at on my slide?
Cytoplasmic signal in elongated or late spermatids is strong; glandular cells in adrenal gland or breast show moderate signal.	This matches the listed high testis signal and medium glandular-cell signals (HPA: tissue IHC). Compare the stained cells and compartment, rather than treating every cell in a positive tissue as equally positive.
Nuclear, sharply membranous or predominantly extracellular staining dominates a section.	That distribution conflicts with CCT2’s cytoplasmic annotation and lack of a transmembrane segment (UniProt P78371: location; topology). Check whether the pattern tracks tissue edges, counterstain or detection background before assigning it to CCT2.
Adipocytes, cardiomyocytes or squamous epithelial cells stain strongly while expected positive cells do not.	HPA lists these cell types as not detected in adipose tissue, heart muscle and esophagus or oral mucosa, respectively (HPA: tissue IHC). Consider cross-reactivity or endogenous detection activity; a positive mark in the wrong cell type does not establish target specificity.
Color is widespread over stroma, lumina or cells without a clear cytoplasmic boundary.	A diffuse deposit cannot be scored confidently against HPA’s cell-resolved cytoplasmic profile (HPA: tissue IHC). Review the negative control, blocking, washes and detection chemistry as general IHC checks, then reassess the staining in identifiable cells.
No signal appears in elongated or late spermatids in a testis section.	These cells are a high-staining reference in HPA’s tissue IHC data (HPA: High in elongated or late spermatids). First verify that they are present and preserved in the section; then review the staining run before concluding that the sample lacks CCT2.

💡Expected CCT2 appearanceA convincing positive is predominantly cytoplasmic, strongest in identifiable elongated or late spermatids and moderate in listed glandular cells; dominant nuclear, membranous or acellular color warrants investigation (HPA: tissue IHC; UniProt P78371: location, topology).

How each factor affects the staining
Cell and tissue selection	HPA reports cytoplasmic expression in most tissues, but its listed cell levels range from high in testis spermatids to not detected in several cell types (HPA: tissue IHC). Score the named cell population, not the organ as a whole.
Antibody evidence	HPA rates tissue IHC Enhanced and lists two rabbit polyclonal antibodies with Enhanced IHC validation, HPA003197 and HPA003198 (HPA: reliability; antibodies). This supports the reference pattern, while its RNA comparison has medium consistency (HPA: reliability description).
Subcellular interpretation	Cytoplasmic localization and absence of a transmembrane segment support intracellular staining (UniProt P78371: location; topology). They do not, by themselves, prove that every cytoplasmic deposit is antibody-specific.
Isoforms and epitope uncertainty	UniProt lists two CCT2 isoforms and nine modified residues (UniProt P78371: isoforms; modified residues). The supplied record gives no antibody epitope, so it cannot predict isoform-specific staining or an effect of those modifications on detection.
IF/ICC Q&A: Where should fluorescence appear?	Mainly in the cytosol; HPA additionally reports signal in the connecting, mid and principal pieces in its subcellular data (HPA: ICC-IF, cytosol supported; additional locations approved). This is an interpretation reference for the separate IF/ICC guide, not an IHC protocol.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Testis control has no visible spermatid signal.	The high-staining cells may be absent from the viewed area, or the IHC run may have failed; HPA reports high signal specifically in elongated or late spermatids (HPA: tissue IHC).	Confirm those cells on the section, then check the run’s controls and general IHC steps, including retrieval, reagent delivery and detection. Do not infer CCT2 absence from a failed run.
Only nuclei or cell borders are strongly colored.	The dominant compartment conflicts with the cytoplasmic CCT2 annotation (UniProt P78371: location; topology). Counterstain, edge deposits or nonspecific detection may complicate reading.	Compare the color with the negative control and intact cell morphology; score only a reproducible cell-associated pattern consistent with the HPA reference (HPA: tissue IHC).
Strong color appears in HPA-listed negative cell types.	Cross-reactivity or endogenous detection activity is possible when adipocytes, cardiomyocytes or listed squamous epithelial cells stain despite their not-detected HPA entries (HPA: tissue IHC).	Identify the exact cell type, inspect the negative control and review the blocking and detection system before calling the stain CCT2-positive.
The entire section has diffuse color.	Diffuse background can obscure the cell-resolved cytoplasmic pattern reported for CCT2 (HPA: tissue IHC).	Review the negative control, washes, blocking and chromogen development as general IHC practice; reassess only after individual stained cells can be distinguished.
A medium-level reference tissue looks weak or patchy.	HPA’s medium calls apply to named populations, such as adrenal glandular cells or bone-marrow hematopoietic cells, rather than every cell in those tissues (HPA: tissue IHC).	Locate the named population and compare it with a high-signal testis reference from the same run (HPA: High in elongated or late spermatids).
The tissue result and an IF/ICC image seem different.	The datasets describe different preparations and locations: HPA tissue IHC reports cytoplasmic expression, while ICC-IF reports mainly cytosolic signal plus approved sperm-piece locations (HPA: tissue IHC; ICC-IF).	Compare matching cell types and compartments. Use the separate IF/ICC guide for fluorescence-specific design; do not transfer its subcellular image pattern into a paraffin-section scoring rule.

Source: UniProt P78371 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing CCT2 staining

IHC analysis of CCT2 using anti-CCT2 antibody (PB9992). CCT2 was detected in paraffin-embedded section of rat gaster tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-CCT2 Antibody (PB9992) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB9992 · IHCIHC analysis of CCT2 using anti-CCT2 antibody (PB9992). CCT2 was detected in paraffin-embedded section of rat gaster tissues. Heat mediated

IHC analysis of CCT2 using anti-CCT2 antibody (PB9992). CCT2 was detected in paraffin-embedded section of human testis tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-CCT2 Antibody (PB9992) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB9992 · IHCIHC analysis of CCT2 using anti-CCT2 antibody (PB9992). CCT2 was detected in paraffin-embedded section of human testis tissues. Heat mediate

IF analysis of CCT2 using anti-CCT2 antibody (PB9992). CCT2 was detected in immunocytochemical section of U20S cell. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 2μg/mL rabbit anti-CCT2 Antibody (PB9992) overnight at 4°C. DyLight®488 Conjugated Goat Anti-Rabbit IgG (BA1127) was used as secondary antibody at 1:100 dilution and incubated for 30 minutes at 37°C. Visualize using a fluorescence microscope and filter sets appropriate for the label used.

PB9992 · IFIF analysis of CCT2 using anti-CCT2 antibody (PB9992). CCT2 was detected in immunocytochemical section of U20S cell. Enzyme antigen retrieva

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000166226-CCT2/tissue/cerebral+cortex#imid_1171856

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000166226-CCT2/tissue/colon#imid_1171774

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000166226-CCT2/tissue/liver#imid_1171783

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000166226-CCT2/tissue/kidney#imid_1171776

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA003198; green = CCT2, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for CCT2 IHC & IF

🧪Run testis first and score elongated or late spermatids for CCT2 staining (HPA: High in elongated or late spermatids). Use adipose tissue as a negative comparator, focusing on adipocytes (HPA: Not detected in adipocytes); on the testis slide, cells without specific staining provide an internal background reference, although HPA does not identify a particular negative cell type there.

Positive control tissue: Testis (Elongated or late spermatids, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CCT2 in A-431, U2OS, RPTEC/TERT1, hTERT-RPE1 (serum starved), Sperm, with annotated localisation: Cytosol (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control, a host- and clonality-matched rabbit isotype control, and identically processed CCT2 knockout material as a biological negative (selected caption: rabbit anti-CCT2 antibody). For testis DAB staining, block endogenous peroxidase and assess endogenous biotin because the selected detection uses a streptavidin–biotin complex (selected caption: SABC with DAB).

⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected paraffin-section caption does not state a fixative (selected caption: fixative not stated). Heat retrieval with citrate buffer at pH 6 for 20 minutes is documented for the selected antibody, but retrieval dependence and whether frozen sections or IF are easier are unreported (selected caption: citrate retrieval). In testis IF, distinguish cytosolic staining from possible sperm-piece signal when scoring elongated or late spermatids (HPA: High in elongated or late spermatids; HPA subcellular: cytosol supported, connecting piece, mid piece and principal piece approved).

HPA tissue IHC evidence for CCT2

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Testis	Elongated or late spermatids	High	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Medium	Protein (IHC)	HPA →
Appendix	Glandular cells	Medium	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Medium	Protein (IHC)	HPA →
Breast	Glandular cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Esophagus	Squamous epithelial cells	Not detected	Protein (IHC)	HPA →
Heart muscle	Cardiomyocytes	Not detected	Protein (IHC)	HPA →
Kidney	Cells in glomeruli	Not detected	Protein (IHC)	HPA →
Oral mucosa	Squamous epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced CCT2 IHC Tips

Troubleshoot CCT2 staining in paraffin sections by checking retrieval, cytoplasmic localisation, controls, and cell specific scoring.

Which retrieval condition should I try first for CCT2 in paraffin sections?

Start with heat mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet PB9992; PB9992 tissue IHC caption). Keep heating, cooling, and section handling consistent across slides so staining differences remain interpretable (standard IHC practice). The demonstrated paraffin section workflow used 1 μg/mL primary antibody overnight at 4°C, followed by biotinylated secondary detection and DAB (PB9992 tissue IHC caption). If cytoplasmic signal remains weak, compare a carefully controlled alternative retrieval condition on adjacent sections, using the same antibody concentration and detection steps (standard IHC practice).

Could fixation explain weak or uneven CCT2 staining?

CCT2 specific sensitivity to fixation is unknown from the supplied evidence; the paraffin section caption does not state a fixative (PB9992 tissue IHC caption). Record the fixative and processing history for each specimen before attributing weak staining to antigen loss (standard IHC practice). Compare sections with similar processing, then assess retrieval and antibody incubation under matched detection conditions (standard IHC practice). Uneven staining near folds, torn areas, or section edges calls for a section quality check before a biological conclusion (standard IHC practice). The observed cytoplasmic pattern does not establish how fixation affects this epitope (HPA tissue IHC; PB9992 tissue IHC caption).

What cellular pattern should a credible CCT2 IHC result show?

Look primarily for cytoplasmic staining: UniProt places CCT2 in the cytoplasm, and tissue IHC reports cytoplasmic expression in most tissues (UniProt P78371 subcellular; HPA tissue IHC). HPA subcellular imaging further supports a mainly cytosolic location (HPA subcellular). Assess signal within intact cells against the counterstain, then compare the same cell population across experimental and control sections (standard IHC practice). A predominantly nuclear, membranous, or extracellular DAB pattern requires scrutiny of morphology, blocking, and detection controls before assignment to CCT2 (UniProt P78371 subcellular; standard IHC practice).

How do isoforms and epitope accessibility affect CCT2 IHC interpretation?

UniProt lists 2 CCT2 isoforms, but the supplied tissue IHC caption does not define the antibody epitope or isoform coverage (UniProt P78371 isoforms; PB9992 tissue IHC caption). Treat a positive DAB signal as CCT2 staining without assigning it to a particular isoform (standard IHC interpretation). CCT2 has no annotated transmembrane segment, so a membrane restricted pattern would need independent support (UniProt P78371 topology). Its recorded acetylation and phosphorylation sites may matter to an epitope only if that epitope overlaps them; no such overlap is established here (UniProt P78371 modified residues; PB9992 tissue IHC caption).

How should I investigate CCT2 by IF alongside paraffin section IHC?

Use the separate IF/ICC workflow to test cytosolic CCT2 signal, and verify that its fixation and antibody conditions are appropriate for the specimen (HPA subcellular; standard IF practice). Because CCT2 has no annotated transmembrane segment and is mainly cytosolic, choose permeabilisation that allows antibody access to the cytosol while preserving cellular morphology (UniProt P78371 topology; HPA subcellular; standard IF practice). Multiplex with a validated marker for the expected cell type, assigning fluorophores to minimise channel overlap and choosing a channel with low tissue autofluorescence (standard IF practice). Include single stain and secondary only controls when judging colocalisation or faint signal (standard IF practice).

How can I distinguish diffuse CCT2 staining from chromogenic background?

Cytoplasmic CCT2 expression across many tissues can make widespread cellular staining plausible, but staining outside intact cells needs separate evaluation (HPA tissue IHC; standard IHC practice). Run a no primary control through the same secondary, enzyme, and DAB steps to reveal detection background (standard IHC practice). Check endogenous peroxidase blocking and, for the demonstrated biotin based detection, consider a control for endogenous biotin contribution (PB9992 tissue IHC caption; standard IHC practice). Compare signal in the expected cell compartments with deposits at section edges, folds, or damaged regions before changing antibody concentration or DAB development (HPA subcellular; standard IHC practice).

What should I measure when comparing CCT2 staining across sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the tissue compartment and eligible intact cells before scoring, then apply the same boundaries to every section (standard IHC practice). Report the percentage of positive cells and staining intensity, or calculate an H-score from intensity weighted percentages on a 0–300 scale (standard IHC practice). Normalise positive counts to the number of eligible cells, or to sampled tissue area as cells per mm², according to the question (standard IHC practice). Keep retrieval, antibody incubation, detection time, imaging, and scoring thresholds matched; HPA reports medium consistency between antibody staining and RNA expression, so avoid treating RNA as an exact staining benchmark (standard IHC practice; HPA tissue IHC).

What evidence makes an apparent CCT2 positive result convincing?

A convincing result shows staining in intact cytoplasm with appropriate controls, consistent with UniProt and HPA localisation (UniProt P78371 subcellular; HPA tissue IHC; standard IHC practice). HPA reports high staining in testis elongated or late spermatids, while adipocytes and cardiomyocytes are listed as not detected; compare the actual cell type rather than the whole tissue label (HPA tissue IHC). Recheck signals confined to nuclei, section edges, necrotic regions, or no primary controls before calling them CCT2 (HPA subcellular; standard IHC practice). Persistent DAB signal in the no primary control points to a detection or endogenous enzyme issue requiring resolution before biological interpretation (standard IHC practice).

Boster reagents

Best CCT2 / T-complex protein 1 subunit beta IHC Antibodies

PB9992 has pictured IHC in paraffin sections of rat and mouse gaster and human testis, plus IF/ICC in U2OS cells (catalog image captions).

Real IHC data

Anti-TCP1 beta/CCT2 Antibody ®

Cat # PB9992

View product →

PB9992 lists IHC and IF/ICC for human, mouse, and rat, with tissue IHC images in all three species and a U2OS IF/ICC image (catalog applications, reactivity, and image captions). M05524-2 lists IHC and IF/ICC for human, mouse, and rat; no image captions were supplied (catalog applications, reactivity, and image captions).

Which to pick: Choose PB9992 for tissue IHC: its own images show paraffin sections with citrate pH 6 retrieval and a 1 μg/ml primary antibody concentration; the fixative is unreported (PB9992 IHC image captions). Choose PB9992 for IF/ICC because its U2OS image documents that application at 2 μg/ml (PB9992 IF image caption). For work across human, mouse, and rat, both SKUs list reactivity, while PB9992 has tissue IHC images in all three species; M05524-2 is a rabbit monoclonal option with no supplied image captions (catalog reactivity, clone, and image captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P78371 (TCPB_HUMAN, T-complex protein 1 subunit beta).
Human Protein Atlas. CCT2 tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. CCT2 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the connecting piece, mid piece and principal piece..
Human Protein Atlas. CCT2 antibody validation summary (2 antibodies).
Comprehensive prognostic and immunological analysis of CCT2 in pan-cancer. Frontiers in oncology 2022 — PMC9476648.
CCT2 enhances c-Myc stabilization to drive tumor progression and chemoresistance in head and neck squamous cell carcinoma. Genes & diseases 2026 — PMC13485502.
Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma. World journal of surgical oncology 2013 — PMC3691597.
Identification of metabolic reprogramming-associated biomarkers in endometriosis through integrated bioinformatics analysis. Hereditas 2025 — PMC12574043.
PubMed PMID:9819444 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:19054851 — UniProt-cited evidence.